Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | NOS1 | P29475 | 2/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200145 | 0.95 | QPCT (0.91) | QPCTKMT2AMEN1ATMHTT | |
| SCHEMBL12835094 | 0.94 | QPCT (0.89) | QPCTKMT2AMEN1ATMKDM4E | |
| SCHEMBL13246359 | 0.92 | QPCT (0.85) | QPCTKMT2AMEN1ATMPOLB | |
| Hydrochloric Acid SCHEMBL2529362 | 0.90 | MEN1 (0.85) | QPCTKMT2AMEN1ATMHTT | |
| SCHEMBL13246337 | 0.88 | QPCT (0.78) | QPCTKMT2AMEN1ATMHTT | |
| SCHEMBL13246341 | 0.87 | QPCT (0.76) | QPCTKMT2AMEN1ATMHTT | |
| SCHEMBL10457427 | 0.84 | QPCT (0.73) | QPCTKMT2AMEN1ATMHTT | |
| SCHEMBL18837209 | 0.84 | QPCT (0.73) | QPCTKMT2AMEN1ATMHTT | |
| SCHEMBL8684902 | 0.84 | QPCT (0.73) | QPCTKMT2AMEN1ATMPOLB | |
| SCHEMBL6302835 | 0.84 | QPCT (0.73) | QPCTKMT2AMEN1ATMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940896-B2 | Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940896-B2 | Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080182866-A1 | Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS , INC. A CORPORATION | 2008-07-31 | — | — | US | disclosed |
| US-20080182866-A1 | Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS , INC. A CORPORATION | 2008-07-31 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | RNMT, VEGFA, VHL | QPCT 267/4885KMT2A 1179/4885MEN1 3024/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | QPCT 1290/4885KMT2A 3947/4885MEN1 4693/4885 |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | QPCT 106/4885KMT2A 929/4885MEN1 4147/4885 |
| US-20080182866-A1 | Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis | VEGFA, TEK, FLT4 | QPCT 685/4885KMT2A 3341/4885MEN1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.